Related references
Note: Only part of the references are listed.Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study
Karen Minde Fagerli et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry
Bente Glintborg et al.
ARTHRITIS AND RHEUMATISM (2013)
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
S. Fenix-Caballero et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50
Maya H. Buch et al.
AUTOIMMUNITY REVIEWS (2012)
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland
P. M. Laws et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Comorbidities of Psoriatic Arthritis -- Metabolic Syndrome and Prevention: A Report from the GRAPPA 2010 Annual Meeting
S. P. RAYCHAUDHURI
JOURNAL OF RHEUMATOLOGY (2012)
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Ustekinumab in clinical practice: response depends on dose and previous treatment
V. Ruiz Salas et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts
Majed Khraishi et al.
CLINICAL RHEUMATOLOGY (2011)
A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs
Ginette Tenga et al.
JOINT BONE SPINE (2011)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
G. Wells et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
D. Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
ASAS/EULAR recommendations for the management of ankylosing spondylitis
J Zochling et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Share Paper
